Back to Journals » Neuropsychiatric Disease and Treatment » Volume 15

Serum BICC1 levels are significantly different in various mood disorders

Authors Chen S, Jiang H, Xu Z, Zhao J, Wang M, Lu Y, Li J, Sun F, Yuan Y

Received 7 October 2018

Accepted for publication 14 December 2018

Published 15 January 2019 Volume 2019:15 Pages 259—265


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Yuping Ning

Suzhen Chen,1,2 Haitang Jiang,1,2 Zhi Xu,1,2 Jingjing Zhao,3 Ming Wang,4 Yan Lu,5 Jianhua Li,6 Fei Sun,7 Yonggui Yuan1,2

1Department of Psychosomatics and Psychiatry, ZhongDa Hospital, School of Medicine, Southeast University, Nanjing 210009, PR China; 2Institute of Psychosomatics, School of Medicine, Southeast University, Nanjing 210009, PR China; 3Department of Psychiatry, Brain Hospital, Nanjing Medical University, Nanjing 210029, PR China; 4Department of Psychiatry, The Third People’s Hospital of Changshu, Suzhou 215500, PR China; 5Department of Psychiatry, The Fourth People’s Hospital of Zhangjiagang, Suzhou 215600, PR China; 6Department of Psychiatry, The Third People’s Hospital of Huzhou, Huzhou 313000, PR China; 7Department of Psychiatry, The Second People’s Hospital of Jingjiang, Taizhou 214500, PR China

Mood disorders are recurrent chronic disorders with fluctuating mood states and energy, and misdiagnosis is common when based solely on clinical interviews because of overlapping symptoms. Because misdiagnosis may lead to inappropriate treatment and poor prognosis, finding an easily implemented objective tool for the discrimination of different mood disorders is very necessary and urgent. However, there has been no accepted objective tool until now. Recently, BICC1 has been identified as a candidate gene relating to major depressive disorder (MDD). Therefore, the aim of this study is to evaluate the ability of serum BICC1 to discriminate between various mood disorders, including MDD and the manic and depressive phases of bipolar disorder, namely bipolar mania (BM) and bipolar depression (BD).
Patients and methods: Serum BICC1 levels in drug-free patients with MDD (n=30), BM (n=30), and BD (n=13), and well-matched healthy controls (HC, n=30) were measured with ELISA kits. Pearson correlation analyses were used to analyze the correlations between serum BICC1 levels and clinical information. Receiver operating characteristic (ROC) curve analysis was used to analyze the differential discriminative potential of BICC1 for different mood disorders.
Results: One-way ANOVA indicated that serum BICC1 levels were significantly increased in all patient groups compared with the HC group and significantly different between each pair of patient groups. Correlation analyses found no relationship between serum BICC1 levels and any clinical variables in any study group. ROC curve analysis showed that serum BICC1 could discriminate among all three mood disorders from each other accurately with fair-to-excellent discriminatory capacity (area under the ROC curve from 0.787 to 1.0).
Conclusion: The findings of this preliminary study indicated significant differences in serum BICC1 levels in patients with different mood disorders. This study provides preliminary evidence that serum BICC1 may be regarded as a promising, objective, easy-to-use tool for diagnosing different mood disorders.

biomarker, mood disorder, diagnosis, differential diagnosis, objective tool, BICC1

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]